Legacy Wealth Management LLC MS Sells 4,788 Shares of Abbott Laboratories $ABT

Posted by George Bondi on Nov 3rd, 2026

Legacy Wealth Management LLC MS reduced its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 24.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,867 shares of the healthcare product maker’s stock after selling 4,788 shares during the quarter. Legacy Wealth Management LLC MS’s holdings in Abbott Laboratories were worth $1,469,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Eads & Heald Wealth Management boosted its stake in shares of Abbott Laboratories by 1.1% in the 3rd quarter. Eads & Heald Wealth Management now owns 12,967 shares of the healthcare product maker’s stock valued at $1,282,000 after purchasing an additional 146 shares during the last quarter. Garde Capital Inc. bought a new stake in shares of Abbott Laboratories during the third quarter worth approximately $210,000. GRIMES & Co WEALTH MANAGEMENT LLC raised its stake in shares of Abbott Laboratories by 25.9% during the third quarter. GRIMES & Co WEALTH MANAGEMENT LLC now owns 135,384 shares of the healthcare product maker’s stock worth $13,380,000 after buying an additional 27,844 shares during the last quarter. Greenfield Seitz Capital Management LLC acquired a new position in Abbott Laboratories in the third quarter valued at approximately $213,000. Finally, Signature Equity Partners LLC lifted its holdings in Abbott Laboratories by 7.9% in the third quarter. Signature Equity Partners LLC now owns 1,363 shares of the healthcare product maker’s stock valued at $135,000 after buying an additional 100 shares during the period. Institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Citigroup reduced their price objective on shares of Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating on the stock in a research note on Thursday, October 22nd. Royal Bank Of Canada cut their price target on Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Thursday, October 22nd. Rothschild & Co Redburn upgraded Abbott Laboratories from a “neutral” rating to a “buy” rating and raised their price target for the stock from $119.00 to $127.00 in a research report on Friday, October 2nd. UBS Group decreased their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Finally, Barclays started coverage on Abbott Laboratories in a report on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $118.32.

Check Out Our Latest Stock Report on ABT

Abbott Laboratories Trading Up 3.8%

NYSE:ABT opened at $110.27 on Tuesday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $132.02. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The stock has a market capitalization of $190.80 billion, a PE ratio of 41.14, a price-to-earnings-growth ratio of 1.80 and a beta of 0.59. The business’s 50-day simple moving average is $104.23 and its 200-day simple moving average is $101.99.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.42. The firm had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a net margin of 9.75% and a return on equity of 17.97%. The company’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.30 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 94.03%.

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.